Compare Recursion Pharmaceuticals Inc (RXRX) vs Teucrium Wheat Fund (WEAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Teucrium Wheat Fund — how do they compare? Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B), while Teucrium Wheat Fund trades at $26.3. The key difference: Teucrium Wheat Fund is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | WEAT | |
|---|---|---|
Market Cap | $1.86B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $6.79 | $28.00 |
52-Week Low | $2.84 | $19.88 |
Enterprise Value | $1.38B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
WEAT, a US-listed wheat ETF, trades at $26.96, up 1.77% today, with a bullish technical signal from moving averages and ADX indicating strong trend momentum. Recent performance shows a 9.9% gain over the past month, driven by inflation concerns and commodity strength. Key support and resistance cluster around $27, suggesting a pivotal price zone.
Outlook remains positive due to inflation hedging demand, but risks include commodity price volatility and Federal Reserve policy shifts. The ETF lacks traditional fundamental metrics like P/E or revenue, relying on wheat futures performance. Investors should weigh macroeconomic trends against potential pullbacks in agricultural markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Teucrium Wheat Fund
WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →
